Sign in

You're signed outSign in or to get full access.

Claire Gulmi

About Claire Gulmi

Independent director since 2018; age 71. Former Executive Vice President and Chief Financial Officer at Envision Healthcare (retired Oct. 2017; advisor through Sept. 2018) and earlier EVP/CFO at AmSurg (from 1994; AmSurg merged with Envision in 2016). Recognized “audit committee financial expert”; BBA in Accounting and Finance from Belmont University .

Past Roles

OrganizationRoleTenureCommittees/Impact
Envision HealthcareExecutive Vice President & Chief Financial Officer; Advisor post-retirementCFO until Oct 2017; Advisor through Sept 2018Led finance at large provider; post-merger integration with AmSurg
AmSurg CorpExecutive Vice President & Chief Financial Officer; DirectorCFO from 1994; Director 2004–2016Board service until 2016 merger with Envision

External Roles

OrganizationRoleTenureCommittees/Impact
Air Methods Corp (public at the time)Director; Audit Committee Chair2015–2017Chaired audit at ~$1.5B public company
Bank of NashvilleAdvisory Board Member2001–2015Advisory oversight
YWCA of Nashville; Nashville Public Radio; Bethlehem Centers of Nashville; Girl Scouts; American Heart Association; All About WomenBoard Chair / Board MemberVariousCivic leadership; multiple board roles
Several privately held companiesDirectorOngoingBoard service

Board Governance

  • Independence: Board determined Gulmi is independent under NYSE rules and SEC Rule 10A-3 .
  • Committee assignments: Compensation Committee Chair; member of Audit Committee (Hensley is Audit Chair); ESG Committee comprises Cotman, Gardner, Van Horn .
  • Financial expertise: Qualifies as “audit committee financial expert”; Audit Committee members deemed financially literate .
  • Attendance and engagement: Board met 4 times in 2024; each director attended >75% of Board and applicable committee meetings. Independent directors held 4 executive sessions in 2024 .
  • Board structure: Independent Chairman (Alan Gardner) leads executive sessions; six directors, annual elections .

Fixed Compensation

ComponentStructure2024 AmountVesting/Terms
Annual cash retainerIncreased from $50,000 to $65,000 beginning with 2024 annual meeting$65,000 (elected in stock) Directors may elect retainer in restricted stock; 3-year cliff vest; additional “restriction multiple” shares for retainer deferral (up to 0.6x for 3-year)
Committee chair feeCompensation Committee Chair$17,500 (elected in stock) Same vesting as retainer deferral
Audit Committee Chair feeNot applicable to GulmiAudit Chair fee stands at $20,000 (Hensley)
Board Chairman feeNot applicable to GulmiChairman retainer $100,000 (Gardner)
2024 Fees paidCash vs. stock mix$82,500 in stock; $0 cashGulmi elected ~100% of retainer/fees in stock

Notes: Compensation consultant (Ferguson Partners Consulting) engaged in 2023 to benchmark director pay; fee $20,000 .

Performance Compensation

ElementStructure2024 Grant ValueMetrics
Annual equity award (restricted stock)Increased to $110,000 grant value beginning 2024; 3-year cliff vest; forfeiture if director resigns/removed before vestingIncluded in “Stock Awards” $158,305 total (grant plus restriction multiple effects on retainer deferrals) No performance conditions; time-based restricted stock only

Goal for director pay mix: 60–75% of total director compensation delivered in restricted stock .

Other Directorships & Interlocks

  • No compensation committee “interlocks” or insider participation requiring disclosure; no member was an officer or employee in 2024 .
  • No related-party transactions requiring disclosure under Item 404(a) .

Expertise & Qualifications

  • CFO leadership across healthcare services; extensive finance/accounting background; designated audit committee financial expert .
  • Public company board experience; governance, risk management and strategic planning exposure as reflected in Board matrix .

Equity Ownership

HolderShares Beneficially Owned% of Shares OutstandingPledging
Claire Gulmi42,493<1% (based on 28,339,419 shares outstanding)No shares pledged as collateral
  • Stock ownership guidelines: Non-employee directors must hold common stock equal to 3x current annual retainer; all directors were in compliance as of March 3, 2025 .
  • Anti-hedging/pledging policy in effect; restricted stock cannot be sold/assigned/pledged during restriction periods .

Governance Assessment

  • Strengths:

    • Independent director with deep CFO experience and designated audit financial expert; chairs Compensation Committee, enhancing oversight of pay-for-performance and clawback policy administration .
    • High engagement (attendance >75%; independent executive sessions); independent Chairman structure supports robust oversight .
    • Strong alignment: Gulmi elected to take 100% of her 2024 retainer/fees in stock; annual equity delivered via multi-year cliff vesting; Company prohibits hedging/pledging and enforces ownership guidelines (in compliance) .
    • Compensation Committee leveraged independent consultant for director pay; Company received ~92% say-on-pay support in 2024, indicating shareholder confidence in compensation governance .
  • Watch items:

    • Concentration of roles (Compensation Chair and Audit member) places significant governance responsibility on one director—appropriate but worth monitoring for workload and independence of judgments .
    • Company-specific headwinds (tenant credit reserve) prompted NEO pay alignment actions; continued oversight by Compensation Committee is critical to maintain investor confidence in pay-performance linkage .
  • Conflicts/related-party risk: None disclosed; Board independence affirmed; no legal proceedings involving directors; robust related-party transaction policy administered by Audit Committee .